pirinixic acid has been researched along with fenofibric acid in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, AD; Berger, JP; Dadiz, A; Doebber, TW; Elbrecht, A; Forrest, MJ; Hu, Z; Jones, AB; MacNaul, KL; Meurer, R; Moller, DE; von Langen, D; Zhou, G | 1 |
| Albrektsen, T; Bury, PS; Deussen, HJ; Din, N; Fleckner, J; Frederiksen, KS; Jeppesen, L; Mogensen, JP; Nehlin, J; Pettersson, I; Sauerberg, P; Svensson, LA; Wulff, EM; Ynddal, L | 1 |
| Conte Camerino, D; Fracchiolla, G; Laghezza, A; Lavecchia, A; Loiodice, F; Mazza, F; Montanari, R; Novellino, E; Piemontese, L; Pierno, S; Pochetti, G; Tortorella, P | 1 |
| Kockx, M; Kooistra, T; Princen, HM | 1 |
| Chopin-Delannoy, S; Dubois, G; Fadel, A; Fruchart, JC; Gervois, P; Kosykh, V; Laudet, V; Najïb, J; Staels, B | 1 |
| Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T | 1 |
| Chinetti, G; Corseaux, D; Duriez, P; Fruchart, JC; Jude, B; Neve, BP; Staels, B; Zawadzki, C | 1 |
| Benéteau, N; Chapuis, V; Colpaert, FC; Dupont-Passelaigue, E; Junquéro, D; Lestienne, F; Patoiseau, JF; Rival, Y; Taillandier, T | 1 |
8 other study(ies) available for pirinixic acid and fenofibric acid
| Article | Year |
|---|---|
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
Topics: Animals; Mandelic Acids; Mice; Mice, Inbred C57BL; Mice, Transgenic; Protein Binding; Rats; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2003 |
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
Topics: Alkenes; Amino Acid Sequence; Animals; Binding Sites; Biological Availability; Cell Line; Crystallography, X-Ray; Dimerization; Humans; Ligands; Male; Mice; Models, Molecular; Molecular Sequence Data; Propionates; Rats; Receptors, Cytoplasmic and Nuclear; Sequence Alignment; Stereoisomerism; Transcription Factors; Transcriptional Activation | 2003 |
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
Topics: Animals; Cell Line, Tumor; Chloride Channels; Chlorides; Clofibric Acid; Crystallography, X-Ray; Drug Discovery; Electric Conductivity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligands; Male; Models, Molecular; Molecular Conformation; Muscle, Skeletal; Muscular Diseases; PPAR alpha; PPAR gamma; Propionates; Rats; Rats, Wistar; Rest; Stereoisomerism; Substrate Specificity | 2009 |
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element.
Topics: Binding Sites; Dimerization; DNA-Binding Proteins; Fenofibrate; Gene Expression Regulation; Humans; Hypolipidemic Agents; Liver; Nuclear Receptor Subfamily 1, Group D, Member 1; Peroxisome Proliferators; Promoter Regions, Genetic; Proteins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Response Elements; Retinoid X Receptors; RNA, Messenger; Transcription Factors | 1999 |
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1999 |
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
Topics: Butyrates; Cells, Cultured; Down-Regulation; Fenofibrate; Humans; Interleukin-1; Lipopolysaccharides; Macrophages; Monocytes; Peroxisome Proliferators; Phenylurea Compounds; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thromboplastin; Transcription Factors | 2001 |
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
Topics: Acetamides; Acetates; Anilides; Cardiovascular Agents; Cell Line; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Macrophages; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mevalonic Acid; Monocytes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tetradecanoylphorbol Acetate; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors | 2004 |